2025

  1. George G, Enting D, Garmo H, Stattin P, Lissbrant IF, Monroy-Iglesias M, Scailteux LM, Balusson F, Van Praet C, Lumen N, Marvaso G, Corrao G, Jereczek-Fossa BA, Chehade L, Shamseddine A, Charafeddine M, Van Hemelrijck M.. Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries. ESMO Real World Data and Digital Oncology, 2025 Mars. Volume . Sammanfattning. Fulltext.
  2. Westerberg M, Garmo H, Bonnedahl J, Eriksson MH, Robinson D, Stattin P, Gedeborg R. Optimised comorbidity indices can reflect patient performance status in register based studies of prostate cancer. Sci Rep. 2025 Dec. Sammanfattning. Fulltext.
  3. Persson AE, Kjellén E, Garmo H, Adrian G, Stattin P, Widmark A, Nilsson P, Gunnlaugsson A. Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC. Radiother Oncol. 2025 Dec. Sammanfattning Fulltext
  4. Alverbratt C, Sandin F, Kolmbäck V, Garmo H, Bratt O, Franck Lissbrant I. Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study. Acta Oncol. 2025 Oct Sammanfattning Fulltext
  5. Westerberg M, Holm L, Garmo H, Stattin P, Gedeborg R. Cohort Profile Update: The National Prostate Cancer Register of Sweden and PCBase. Int J Epidemiol. 2025 Aug. Sammanfattning Fulltext
  6. Irenaeus S, Garmo H, Gedeborg R, Ahlberg M, Robinson D, Stattin P, Beckmann K. Potential gains from radical treatment of men with prostate cancer according to life expectancy. BJUI Compass. 2025 Sep. Sammanfattning Fulltext
  7. Lin E, Garmo H, Beckmann K, Bratt O, Akre O, Stattin P, Gedeborg R. Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons. Int J Cancer. 2025 Sep 9. Sammanfattning Fulltext
  8. Zaurito P, Westerberg M, Garmo H, Gedeborg R, Ventimiglia E, Orrason AW, Thellenberg-Karlsson C, Stattin P, Robinson D. Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score. BJU Int. 2025 Sep. Sammanfattning Fulltext
  9. Renata Zelic, Marcus Westerberg, Pär Stattin, Hans Garmo, Lorenzo Richiardi, Olof Akre, Andreas Pettersson. Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer–specific Death in Sweden: A Population-based Cohort Study, European Urology Open Science, 2025. Fulltext
  10. Scilipoti P, Bratt O, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer. J Natl Compr Canc Netw. 2025 Jul. Sammanfattning Fulltext
  11. Ventimiglia, E., Gedeborg, R., Orrason, A. W., Zaurito, P., Garmo, H., Stattin, P., & Westerberg, M.  A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. Scandinavian Journal of Urology, 2025 June.
  12. Zaurito, P., Garmo, H., Gedeborg, R., Ahlberg, M., Orrason, A. W., Styrke, J., Robinson, D., Stattin, P., Westerberg, M. (2025). Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study. Scandinavian Journal of Urology. 2025 May. Sammanfattning Fulltext
  13. Strömberg U, Bonander C, Garmo H, Lambe M, Stattin P, Bratt O. Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity. Acta Oncol. 2025 May. Sammanfattning Fulltext
  14. Ventimiglia E, Gedeborg R, Styrke J, Orrason AW, Stattin P, Westerberg M. Radical Treatment for Prostate Cancer in Men with Limited Life Expectancy. JAMA Network Open. 2025. Sammanfattning Fulltext
  15. Crump C, Stattin P, Brooks JD, Sundquist J, Wei J, Sieh W, Sundquist K. Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden. Eur Urol Oncol. 2025 Apr. Sammanfattning Fulltext
  16. Koss Modig K, Arnsrud Godtman R, Carlsson S, Stattin P, Styrke J, Månsson M, Stranne J. Patient- and Procedure-specific Risk Factors for Urinary Incontinence After Robot-assisted Radical Prostatectomy: A Nationwide, Population-based Study. Eur Urol Oncol. 2025 Apr. Sammanfattning Fulltext
  17. Egevad L, Micoli C, Delahunt B, Samaratunga H, Garmo H, Stattin P, Eklund M. Time trends in Gleason score distribution among Gleason score 8 and 9-10 cancers. J Clin Pathol. 2025 Mar. Sammanfattning
  18. Orrason AW, Scilipoti P, Garmo H, Gedeborg R, Styrke J, Westerberg M. Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based study. Scand J Urol. 2025 Feb Sammanfattning Fulltext
  19. Corsini C, Scilipoti P, Orrason AW, Gedeborg R, Westerberg M, Stattin P. Functional outcomes after primary versus delayed robot-assisted radical prostatectomy following active surveillance. JNCI Cancer Spectr. 2025 Feb. Sammanfattning Fulltext
  20. Egevad L, Micoli C, Delahunt B, Samaratunga H, Garmo H, Stattin P, Eklund M. Gleason scores provide more accurate prognostic information than grade groups. Pathology. 2025 Jan. Sammanfattning Fulltext
  21. Scilipoti P, Garmo H, Gedeborg R, Robinson D, Stattin P, Westerberg M. Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study. J Natl Cancer Inst. 2025 Jan. Sammafattning Fulltext